Citigroup Inc Dyne Therapeutics, Inc. Transaction History
Citigroup Inc
- $217 Billion
- Q3 2025
A detailed history of Citigroup Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 33,385 shares of DYN stock, worth $582,234. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,385
Previous 61,527
45.74%
Holding current value
$582,234
Previous $585,000
27.86%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
125MCall Options Held
36.5KPut Options Held
74.3K-
Vanguard Group Inc Valley Forge, PA9.76MShares$170 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$169 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$165 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$159 Million19.12% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$129 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $903M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...